DOCSLIB.ORG

Convenient Syntheses of Cytidine 5'-Triphosphate, Guanosine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Reprinted from The Journal of Organic Chemistry, 1990,Vol. 55. Copyright O 1990by the American Chemical Society and reprinted by permission of the copyright owner. Convenient Synthesesof Cytidine 5'-Triphosphate,Guanosine 5'-Triphosphate,and Uridine S'-Triphosphateand Their Use in the Preparation of UDP-glucose,UDP-glucuronic Acid, and GDP-mannose Ethan S. Simon,l Sven Grabowski,2 and George M. Whitesides* Department of Chemistry,Haruard Uniuersity,Cambridge, Massachusetts 02138 ReceiuedSeptember 20, 1989 This paper comparesenzymatic and chemical methods for the synthesisof cy'tidine 5'-triphosphate, guanosine 5'-triphosphate,and uridine 5'-triphosphate from the correspondingnucleoside monophosphates on scalesof - 10 g. Thesenucleoside triphosphates are important as intermediatesin l,eloir pathwavbiosl'ntheses of complex carboh'n'drates;the nucleosidemonophosphates are readilvavailairle <'onrmerciallr'. The bestroute to CTP is basedon phosphi-rn'lationof C\{P usingadenvlate kinase (FlC:.;.-1.:l): the ror.tteto (}TP involvesphosphorylation of GI\{Pusing guanl'late kinase (EC 2.;..1.81:chemicaldeaniination ol ('T}) tpreparedenzvmaticallv from CMP) is the bestsynthesis of UTP. For the 10-200-mmol-scalereactions described in this paper.it is moreconvenient to preparephosphoenolpyruvate (PEP), usedin the enz-vmaticpreparations. from o-(-)-3-phosphoglycericacid (3-PGA) in the reaction mixture rather than to synthesizePEP in a separatechemical step. The in situ conversion of 3-PGA to PEP requiresthe coupledaction of phosphoglyceratemutase (EC 2.7.5.3)and enolase(EC 4.2.L.L1). The enzyme-catalyzedsyntheses of uridine 5'-diphosphoglucose(UDP-Glc), uridine 5'-diphosphoglucuronicacid (UDP-GIcUA), and guanosine5'-diphosphomannose (GDP-Man) illustrate the use of the nucleosidetriphosphates. Introduction that generatethe NTPs and nucleosidephosphate sugars As part of a broad program3to developsynthetic tech- as stoichiometricreagents, rather than relying on their niquesbased on glycosyltransferases for the preparation generationin situ, for five reasons. First, this type of of glycoproteins,glycolipids, and proteoglycans.4we wished approachis the most practical. Developingcomplex sys- to developconvenient routes to cytidine 5'-triphosphate tems of coupledenzymes is difficult. If the synthesesof (CTP),guanosine 5'-triphosphate (GTP), and uridine5'- the NTPs and nucleosidephosphate sugars can be de- triphosphate (UTP). Enzyme-calafyzedreactions of these veloped and optimized separately,the final systemsare three compoundswith monosaccharidesare central reac- simpler. Second,this approachhas greatergenerality. If tions in the biosynthesisof the nucleosidephosphate sugars convenient routes to all of the NTPs and nucleoside required by glycosyl transferasesin mammalian biochem- phosphatesugars can be developed,these compounds are istry (CMP-NeuAc, GDP-Fuc, GDP-Man, UDP-Gal, then available for the full range of oligo- and poly- UDP-GalNAc, UDP-GIc, UDP-GIcNAc, UDP-GIcUA, and saccharidesyntheses. Third, this approach is the most UDP-Xyl).3 flexible. By conducting synthesesof these compounds An important issue in planning synthetic tactics con- separately,it is possibleto use whatever synthetic method cernsthe method of synthesizingthe NTPs and nucleoside works best for each,without concern for the compatibility phosphate sugarsfor use in enzyme-catalyzedreactions: of these methods. Fourth, separating synthesesof the should they be synthesized independently and used as nucleosidephosphate sugarsfrom the steps involving use stoichiometric reagents(in which casechemical, enzymatic of these compoundsin forming glycosidicbonds permits or fermentation syntheseswould all, in principle, be ac- the latter reactions to be conducted in a way that optimizes ceptable)or should they be generatedand usedin situ (in the use of the glycosyl transferases(normally the most which caseonly enzymaticsyntheses would be acceptable)? difficult enzymesto obtain and use).3 Finally, this ap- We have decided initially to develop synthetic methods proach is more likely to be successfulfor the synthesisof unnatural compounds, where analoguesof the natural reactants may have to be synthesizedchemically. (1) DuPont Fellow 1986-87. (2) NATO Postdoctoral Fellow 1988-89 (administered by the CTP, GTP, and UTP are all available from commercial DeutscherAkademischer Austauschdienst). sources,but their cost precludestheir use in multigram- (3) Toone, E. J.; Simon, E. S.; Bednarski, M. D.; Whitesides,G. M. scalereactions. We do not discussin detail the synthesis Tetrahedron 19E9,45, 5365. (4) Sharon, N. Complex Carbohydrates;Addison-Wesley: Reading, of adenosine 5'-triphosphate (ATP) here becauseit is MA. 19?5. relatively inexpensivecompared with other NTPs,5 and 0022-3263lg0 11955-1834$02.50/0O 1990American Chemical Societv ConvenientSyntheses of Nucleoside5'-Triphosphates 1990 1835 Table I. Scale and Yields for Enzymatic Synthesis of Nucleoside Triphosphates NTP enzymeo phosphoryldonorb ,,1 reaction time (days) 1lll,r.lr,t )I'Pjlfj!.? CTP AdK 3-PGA I li tltjt 3 GTP GK 3-PGA ll t.jt 3 GK PEP ll r,rrir 3 AdK (Mn2+) PEP 3, no reactn AdK (Mn2+lMg'*) PEP ll. no reactn UTP AdK 3-PGA 12rf)l I 5 NMPK 3-PGA I()(;8r 1L):in6srnplsls NMPK PEP 6 (92) I AdK (Mnz+) PEP 0.92' :l AdK PEI) 1.16' :l AdK (Mn2+lMe'*) PEP 0.92, ,) ATP AdK 3-PGA e (91) I 'Magnesium(ll) was present in all teactions unlessnoted otherwise. AdK = adenylatekinase (EC 2.?.4.3);GK = guanr.larekinase (EC 2.7.4.8);NMPK = nucl€osidemonophosphatekinase (EC 2.7.4.4). 63-PGA = D-(-)-3-phosphoglycericacid; PEP = phosphoenolpl-ruvate. 'Product was not aBsayed. becauseit has already been synthesizedenzymatically on Scheme I.o Enzymatic Synthesis of Nucleoside a 50-mmoi scale.6 Triphosphates Objective. Our objectivein this work was to develop convenientsyntheses on - 10-gscale of CTP. CiT'I',and UTP of suf'ficientpurity for use in enzyme-catall'zedre- actions. Four strategiescan be usedto produceN'fPs: (l ) enzynatic svnthesis(using cell-free enzt'rnes). (2) chemical s5trthesis,(ll) fermentation,and (4) isolationfrom natural d O'l H OP sources"We consideredthe latter two methodsto be too rpo / 'coo- - 2HO ,1. unfamiliar to be useful in classicalsynthetic organic coo- chemistry laboratoriesand did not investigatetheir merits. , i"oo- We provide conclude that enzymatic methods the most "(i) Phosphoglyceratemutase (EC, 2.7.5.3);(ii) enolase(ECl convenientroutes to CTP and GTP. Chemicaldeamina- ,t.2.L.11);(iii) pyruvatekinase (EC 2.7.I.40);(iv) adenylatekinase tion of CTP (producedenzymatically) is the best route to {8C2.1.4.3,X = A, C, U), guanylatekinase (EC 2.?.4.8,X = G) or UTP. nucleosidemonophosphate kinase (EC 2.7.4.4,X = U). P - phos- Methods of Enzymatic Synthesis. Enzymatic con- phate. Table I listsscales and yields. versionof a NMP to a NTP requirestwo kinases: one for kina-ses.cvtidvl kinase (EC 2.7.4.14)and uridyl kinase7(EC NMP and one fbr NDP (eq 1). The synthesisof N'I'Ps :.;. 1.-iil)ai'e nr)1 t.'()ntmercial prodtrcts. Nucleosidemono- KiNASC1. 1r[1i;.1vi1;1tr.kina.e rr:e:A'l'l) to phosphorvlateAMP, CMP, NMP NDP \TP {1i ( ;\11'..rritl [ \ll'. frcimNDPs is straightforw'ard.Three kinasesare available A:eriou> clriirrbackto the useot N\IPK is its instabiiity that convertall tour of the NDPs (ADP. CDP. GDP. and and cost. F urtlierrnore. preparations of NMPK are not UDP) to the correspondingNTPs: pyruvatekinase; (PK. homogeneous, and a mixture of kinases may actually be EC 2.7.1.40)uses phosphoenolpyruvate (PEP) as a phos- present. Because adenylate kinase is the least expensive phoryl donor, acetate kinase?(EC 2.7.2.1)uses acetyl and most stable of these three kinases, we tried to use it phosphate,ffi d nucleosidediphosphatekinase? (EC 2.7.4.6) to phosphorylate UMP and GMP. We were able to con- usesATP. We chosepyruvate kinaseas kinase2 because vert UMP to UDP using adenylate kinase, but not GMP PEP is more stable than acetyl phosphate and pyruvate to GDP. kinaseis lessexpensive than nucleosidediphosphate ki- Many kinasesuse A'IP as a phosphorylatingagent. nase.5 ATP usuallyis recvcledfrom ADP by using p,vruvateki- The preparation of NDPs from NMPs is more difficult naseand PEPl2'r3or acetatekinase and acetvlphosphate.la than the preparation of NTPs from NDPs. No one, stable, A recentrevie$ sunrrnarizesthe relativemerits of these inexpensive enzyme is known that converts all of the two methodstr) regenerateAl'P in organicsynthesis.5 NMPs to NDPs. We examined three commerciallv PEP is more stablein soluttr)nthan is acetylphosphate availablekinases: adenylatekinase8 (AdK, EC 2.7.4.3), and is thernrodvnanrirallva strongerphosphoryl donor.s guanylatekinase? (GK, EC 2.7.4.8),and nucleosidemono- Commercial['Fl[' i.. hos'ever.too expensive($a800/mol) phosphatekinase? (NMPK, EC 2.7.4.q. In vivo, adenyiate t() usein re'actions,rltii preparative scale (>50 mmol of kinasephosphorylates AMP and guanylatekinase7 phos- PEP is reqtrireclfirr the largerreactiorls described in this phorylates GMP. Adenylate kinase also phosphorylates paper),so il must be svnthesizedin a separatestep. For CMP at synthetically useful rates.e,loTwo other specific this work, we developeda convenientmethod (the PGA method, SchemeI t lirr the enzymaticsynthesis of PEP from the relativeiv inexpensiveo-(-)-3-phosphoglyceric (5) Chenault,H. K.; Simon, E. S.;Whitesides, G. M.In Biatechnologl, acid (il-PGA,$2501mol).15 & Genetic Engineering Reuiews;Russell, G. E., Ed.; Intercept: Wim- borne,Dorset, 1988; Vol.6, Chapter6. (6) Kim, M.-J.; Whitesides,G. M. Biotechnol,Bioeng.
Recommended publications
  • 2'-Deoxyguanosine Toxicity for B and Mature T Lymphoid Cell Lines Is Mediated by Guanine Ribonucleotide Accumulation

    2'-Deoxyguanosine Toxicity for B and Mature T Lymphoid Cell Lines Is Mediated by Guanine Ribonucleotide Accumulation

    2'-deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation. Y Sidi, B S Mitchell J Clin Invest. 1984;74(5):1640-1648. https://doi.org/10.1172/JCI111580. Research Article Inherited deficiency of the enzyme purine nucleoside phosphorylase (PNP) results in selective and severe T lymphocyte depletion which is mediated by its substrate, 2'-deoxyguanosine. This observation provides a rationale for the use of PNP inhibitors as selective T cell immunosuppressive agents. We have studied the relative effects of the PNP inhibitor 8- aminoguanosine on the metabolism and growth of lymphoid cell lines of T and B cell origin. We have found that 2'- deoxyguanosine toxicity for T lymphoblasts is markedly potentiated by 8-aminoguanosine and is mediated by the accumulation of deoxyguanosine triphosphate. In contrast, the growth of T4+ mature T cell lines and B lymphoblast cell lines is inhibited by somewhat higher concentrations of 2'-deoxyguanosine (ID50 20 and 18 microM, respectively) in the presence of 8-aminoguanosine without an increase in deoxyguanosine triphosphate levels. Cytotoxicity correlates instead with a three- to fivefold increase in guanosine triphosphate (GTP) levels after 24 h. Accumulation of GTP and growth inhibition also result from exposure to guanosine, but not to guanine at equimolar concentrations. B lymphoblasts which are deficient in the purine salvage enzyme hypoxanthine guanine phosphoribosyltransferase are completely resistant to 2'-deoxyguanosine or guanosine concentrations up to 800 microM and do not demonstrate an increase in GTP levels. Growth inhibition and GTP accumulation are prevented by hypoxanthine or adenine, but not by 2'-deoxycytidine.
  • We Have Previously Reported' the Isolation of Guanosine Diphosphate

    We Have Previously Reported' the Isolation of Guanosine Diphosphate

    VOL. 48, 1962 BIOCHEMISTRY: HEATH AND ELBEIN 1209 9 Ramel, A., E. Stellwagen, and H. K. Schachman, Federation Proc., 20, 387 (1961). 10 Markus, G., A. L. Grossberg, and D. Pressman, Arch. Biochem. Biophys., 96, 63 (1962). "1 For preparation of anti-Xp antisera, see Nisonoff, A., and D. Pressman, J. Immunol., 80, 417 (1958) and idem., 83, 138 (1959). 12 For preparation of anti-Ap antisera, see Grossberg, A. L., and D. Pressman, J. Am. Chem. Soc., 82, 5478 (1960). 13 For preparation of anti-Rp antisera, see Pressman, D. and L. A. Sternberger, J. Immunol., 66, 609 (1951), and Grossberg, A. L., G. Radzimski, and D. Pressman, Biochemistry, 1, 391 (1962). 14 Smithies, O., Biochem. J., 71, 585 (1959). 15 Poulik, M. D., Biochim. et Biophysica Acta., 44, 390 (1960). 16 Edelman, G. M., and M. D. Poulik, J. Exp. Med., 113, 861 (1961). 17 Breinl, F., and F. Haurowitz, Z. Physiol. Chem., 192, 45 (1930). 18 Pauling, L., J. Am. Chem. Soc., 62, 2643 (1940). 19 Pressman, D., and 0. Roholt, these PROCEEDINGS, 47, 1606 (1961). THE ENZYMATIC SYNTHESIS OF GUANOSINE DIPHOSPHATE COLITOSE BY A MUTANT STRAIN OF ESCHERICHIA COLI* BY EDWARD C. HEATHt AND ALAN D. ELBEINT RACKHAM ARTHRITIS RESEARCH UNIT AND DEPARTMENT OF BACTERIOLOGY, THE UNIVERSITY OF MICHIGAN Communicated by J. L. Oncley, May 10, 1962 We have previously reported' the isolation of guanosine diphosphate colitose (GDP-colitose* GDP-3,6-dideoxy-L-galactose) from Escherichia coli 0111-B4; only 2.5 umoles of this sugar nucleotide were isolated from 1 kilogram of cells. Studies on the biosynthesis of colitose with extracts of this organism indicated that GDP-mannose was a precursor;2 however, the enzymatically formed colitose was isolated from a high-molecular weight substance and attempts to isolate the sus- pected intermediate, GDP-colitose, were unsuccessful.
  • Reversibility Ofthe Pyrophosphoryl Transfer from ATP to GTP By

    Reversibility Ofthe Pyrophosphoryl Transfer from ATP to GTP By

    Proc. Nat. Acad. Sci. USA Vol. 71, No. 9, pp. 3470-3473, September 1974 Reversibility of the Pyrophosphoryl Transfer from ATP to GTP by Escherichia coli Stringent Factor (guanosine 5'-diphosphate-3'-diphosphate/guanosine 5'-triphosphate-3'-diphosphate/relaxed control/ribosomes) JOSE SY The Rockefeller University, New York, N.Y. 10021 Communicated by Fritz Lipmann, July 1, 1974 ABSTRACT The stringent factor-catalyzed, ribosome- was incubated for 60 min at 300 in a 1W0-1 mixture contain- dependent synthesis of guanosine polyplosphates is ing: 50 mM Tris OAc, pH 8.1; 4 mM dithiothreitol; 20 mM found to be reversible. The reverse reaction specifically requires 5'-AMP as the pyrophosphoryl acceptor, and Mg(OAc)2; 5 mM ATP; 10 ,ug of poly(A, U, G); 27 pgof tRNA; guanosine 5'-triphosphate-3'-diphospbate is preferentially 90',g of ethanol-washed ribosomes; and 2 p&g of fraction II utilized as the pyrophosphoryl donor. The primary prod- stringent factor. By minimizing GTPase activity with the ucts of the reaction are GTP and ANP. The reverse reaction use of high Mg++ concentration and ethanol-washed ribo- is strongly inhibited by the antibiotics thiostrepton and a ob- tetracycline, and b' A P and,1-y-pnethylene-adenosixie- somes with a minimal time of incubation, product is triphosphate, but not by ADP, GTP, and GIDP. The reverse tained that is more than 95% pppGpp. After incubation, 1 Al reaction occurs under conditions for nonribosomal syn- of 88% HCOOH was added and the resulting precipitate dis- thesis. The ove'rill reaction for stringent factor-catalyzed carded.
  • Bioenergetics, ATP & Enzymes

    Bioenergetics, ATP & Enzymes

    Bioenergetics, ATP & Enzymes Some Important Compounds Involved in Energy Transfer and Metabolism Bioenergetics can be defined as all the energy transfer mechanisms occurring within living organisms. Energy transfer is necessary because energy cannot be created and it cannot be destroyed (1st law of thermodynamics). Organisms can acquire energy from chemicals (chemotrophs) or they can acquire it from light (phototrophs), but they cannot make it. Thermal energy (heat) from the environment can influence the rate of chemical reactions, but is not generally considered an energy source organisms can “capture” and put to specific uses. Metabolism, all the chemical reactions occurring within living organisms, is linked to bioenergetics because catabolic reactions release energy (are exergonic) and anabolic reactions require energy (are endergonic). Various types of high-energy compounds can “donate” the energy required to drive endergonic reactions, but the most commonly used energy source within cells is adenosine triphosphate (ATP), a type of coenzyme. When this molecule is catabolized (broken down), the energy released can be used to drive a wide variety of synthesis reactions. Endergonic reactions required for the synthesis of nucleic acids (DNA and RNA) are exceptions because all the nucleotides incorporated into these molecules are initially high-energy molecules as described below. The nitrogenous base here is adenine, the sugar is the pentose monosaccharide ribose and there are three phosphate groups attached. The sugar and the base form a molecule called a nucleoside, and the number of phosphate groups bound to the nucleoside is variable; thus alternative forms of this molecule occur as adenosine monophosphate (AMP) and adenosine diphosphate (ADP).
  • Inosine in Biology and Disease

    Inosine in Biology and Disease

    G C A T T A C G G C A T genes Review Inosine in Biology and Disease Sundaramoorthy Srinivasan 1, Adrian Gabriel Torres 1 and Lluís Ribas de Pouplana 1,2,* 1 Institute for Research in Biomedicine, Barcelona Institute of Science and Technology, 08028 Barcelona, Catalonia, Spain; [email protected] (S.S.); [email protected] (A.G.T.) 2 Catalan Institution for Research and Advanced Studies, 08010 Barcelona, Catalonia, Spain * Correspondence: [email protected]; Tel.: +34-934034868; Fax: +34-934034870 Abstract: The nucleoside inosine plays an important role in purine biosynthesis, gene translation, and modulation of the fate of RNAs. The editing of adenosine to inosine is a widespread post- transcriptional modification in transfer RNAs (tRNAs) and messenger RNAs (mRNAs). At the wobble position of tRNA anticodons, inosine profoundly modifies codon recognition, while in mRNA, inosines can modify the sequence of the translated polypeptide or modulate the stability, localization, and splicing of transcripts. Inosine is also found in non-coding and exogenous RNAs, where it plays key structural and functional roles. In addition, molecular inosine is an important secondary metabolite in purine metabolism that also acts as a molecular messenger in cell signaling pathways. Here, we review the functional roles of inosine in biology and their connections to human health. Keywords: inosine; deamination; adenosine deaminase acting on RNAs; RNA modification; translation Citation: Srinivasan, S.; Torres, A.G.; Ribas de Pouplana, L. Inosine in 1. Introduction Biology and Disease. Genes 2021, 12, 600. https://doi.org/10.3390/ Inosine was one of the first nucleobase modifications discovered in nucleic acids, genes12040600 having been identified in 1965 as a component of the first sequenced transfer RNA (tRNA), tRNAAla [1].
  • Questions with Answers- Nucleotides & Nucleic Acids A. the Components

    Questions with Answers- Nucleotides & Nucleic Acids A. the Components

    Questions with Answers- Nucleotides & Nucleic Acids A. The components and structures of common nucleotides are compared. (Questions 1-5) 1._____ Which structural feature is shared by both uracil and thymine? a) Both contain two keto groups. b) Both contain one methyl group. c) Both contain a five-membered ring. d) Both contain three nitrogen atoms. 2._____ Which component is found in both adenosine and deoxycytidine? a) Both contain a pyranose. b) Both contain a 1,1’-N-glycosidic bond. c) Both contain a pyrimidine. d) Both contain a 3’-OH group. 3._____ Which property is shared by both GDP and AMP? a) Both contain the same charge at neutral pH. b) Both contain the same number of phosphate groups. c) Both contain the same purine. d) Both contain the same furanose. 4._____ Which characteristic is shared by purines and pyrimidines? a) Both contain two heterocyclic rings with aromatic character. b) Both can form multiple non-covalent hydrogen bonds. c) Both exist in planar configurations with a hemiacetal linkage. d) Both exist as neutral zwitterions under cellular conditions. 5._____ Which property is found in nucleosides and nucleotides? a) Both contain a nitrogenous base, a pentose, and at least one phosphate group. b) Both contain a covalent phosphodister bond that is broken in strong acid. c) Both contain an anomeric carbon atom that is part of a β-N-glycosidic bond. d) Both contain an aldose with hydroxyl groups that can tautomerize. ___________________________________________________________________________ B. The structures of nucleotides and their components are studied. (Questions 6-10) 6._____ Which characteristic is shared by both adenine and cytosine? a) Both contain one methyl group.
  • Central Nervous System Dysfunction and Erythrocyte Guanosine Triphosphate Depletion in Purine Nucleoside Phosphorylase Deficiency

    Central Nervous System Dysfunction and Erythrocyte Guanosine Triphosphate Depletion in Purine Nucleoside Phosphorylase Deficiency

    Arch Dis Child: first published as 10.1136/adc.62.4.385 on 1 April 1987. Downloaded from Archives of Disease in Childhood, 1987, 62, 385-391 Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency H A SIMMONDS, L D FAIRBANKS, G S MORRIS, G MORGAN, A R WATSON, P TIMMS, AND B SINGH Purine Laboratory, Guy's Hospital, London, Department of Immunology, Institute of Child Health, London, Department of Paediatrics, City Hospital, Nottingham, Department of Paediatrics and Chemical Pathology, National Guard King Khalid Hospital, Jeddah, Saudi Arabia SUMMARY Developmental retardation was a prominent clinical feature in six infants from three kindreds deficient in the enzyme purine nucleoside phosphorylase (PNP) and was present before development of T cell immunodeficiency. Guanosine triphosphate (GTP) depletion was noted in the erythrocytes of all surviving homozygotes and was of equivalent magnitude to that found in the Lesch-Nyhan syndrome (complete hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency). The similarity between the neurological complications in both disorders that the two major clinical consequences of complete PNP deficiency have differing indicates copyright. aetiologies: (1) neurological effects resulting from deficiency of the PNP enzyme products, which are the substrates for HGPRT, leading to functional deficiency of this enzyme. (2) immunodeficiency caused by accumulation of the PNP enzyme substrates, one of which, deoxyguanosine, is toxic to T cells. These studies show the need to consider PNP deficiency (suggested by the finding of hypouricaemia) in patients with neurological dysfunction, as well as in T cell immunodeficiency. http://adc.bmj.com/ They suggest an important role for GTP in normal central nervous system function.
  • 1/05661 1 Al

    1/05661 1 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . ... - 12 May 2011 (12.05.2011) W 2 11/05661 1 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/00 (2006.0 1) C12Q 1/48 (2006.0 1) kind of national protection available): AE, AG, AL, AM, C12Q 1/42 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 10/054171 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 26 October 2010 (26.10.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/255,068 26 October 2009 (26.10.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, MYREXIS, INC.
  • Role of Uridine Triphosphate in the Phosphorylation of 1-ß-D- Arabinofuranosylcytosine by Ehrlich Ascites Tumor Cells1

    Role of Uridine Triphosphate in the Phosphorylation of 1-ß-D- Arabinofuranosylcytosine by Ehrlich Ascites Tumor Cells1

    [CANCER RESEARCH 47, 1820-1824, April 1, 1987] Role of Uridine Triphosphate in the Phosphorylation of 1-ß-D- Arabinofuranosylcytosine by Ehrlich Ascites Tumor Cells1 J. Courtland White2 and Leigh H. Hiñes Department of Biochemistry, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103 ABSTRACT potent feedback regulation by dCTP (3-9). The level of dCTP in the cell has been shown to be an important determinant of Pyrimidine nucleotide pools were investigated as determinants of the ara-C action in a variety of cell types (10-12). For example, rate of phosphorylation of l-j9-D-arabinofuranosylcytosine (ara-C) by Harris et al. (10) demonstrated that the sensitivity of several Ehrlich ascites cells and cell extracts. Cells were preincubated for 2 h with 10 MMpyrazofurin, 10 imi glucosamine, 50 MM3-deazauridine, or mouse tumor cell lines to ara-C was inversely proportional to 1 HIMuridine in order to alter the concentrations of pyrimidine nucleo- their cellular dCTP level. In addition, these authors observed tides. Samples of the cell suspensions were taken for assay of adenosine that thymidine enhanced ara-C sensitivity in those cell lines S'-triphosphate (ATP), uridine 5'-triphosphate (IIP), cytidine S'-tn- where there was a depression in dCTP levels but not in those phosphate, guanosine S'-triphosphate, deoxycytidine S'-triphosphate cell lines where thymidine did not alter dCTP pools. Cellular (dCTP), and deoxythymidine S'-triphosphate; then l MM[3H|ara-C was pools of dCTP may also be decreased by inhibitors of the de added and its rate of intrazellular uptake was measured for 30 min.
  • Guanosine Pentaphosphate Phosphohydrolase of Escherichia Coli Is a Long-Chain Exopolyphosphatase J

    Guanosine Pentaphosphate Phosphohydrolase of Escherichia Coli Is a Long-Chain Exopolyphosphatase J

    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 7029-7033, August 1993 Biochemistry Guanosine pentaphosphate phosphohydrolase of Escherichia coli is a long-chain exopolyphosphatase J. D. KEASLING*, LEROY BERTSCHt, AND ARTHUR KORNBERGtI *Department of Chemical Engineering, University of California, Berkeley, CA 94720-9989; and tDepartment of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305-5307 Contributed by Arthur Kornberg, April 14, 1993 ABSTRACT An exopolyphosphatase [exopoly(P)ase; EC MATERIALS AND METHODS 3.6.1.11] activity has recently been purified to homogeneity from a mutant strain of Escherichia coi which lacks the Reagents and Proteins. Sources were as follows: ATP, principal exopoly(P)ase. The second exopoly(P)ase has now ADP, nonradiolabeled nucleotides, poly(P)s, bovine serum been identified as guanosine pentaphosphate phosphohydro- albumin, and ovalbumin from Sigma; [y-32P]ATP at 6000 lase (GPP; EC 3.6.1.40) by three lines of evidence: (i) the Ci/mmol (1 Ci = 37 GBq) and [y-32P]GTP at 6000 Ci/mmol sequences of five btptic digestion fragments of the purified from ICN; Q-Sepharose fast flow, catalase, aldolase, Super- protein are found in the translated gppA gene, (u) the size ofthe ose-12 fast protein liquid chromatography (FPLC) column, protein (100 kDa) agrees with published values for GPP, and and Chromatofocusing column and reagents from Pharmacia (iu) the ratio of exopoly(P)ase activity to GPP activity remains LKB; DEAE-Fractogel, Pll phosphocellulose, and DE52 constant throughout a 300-fold purification in the last steps of DEAE-cellulose from Whatman; protein standards for SDS/ the procedure.
  • GUANOSINE TRIPHOSPHATE* Protein Synthesis Accompanying the Regeneration of Rat Liver Offered a Dramatic One Could Reproduce in V

    GUANOSINE TRIPHOSPHATE* Protein Synthesis Accompanying the Regeneration of Rat Liver Offered a Dramatic One Could Reproduce in V

    1184 BIOCHEMISTRY: HOAGLAND ET AL. PROC. N. A. S. and Structure of Macromolecules, Cold Spring Harbor Symposia on Quantitative Biology, vol. 28 (1963), p. 549. 3 Speyer, J., P. Lengyel, C. Basilio, A. J. Wahba, R. S. Gardner, and S. Ochoa, in Synthesis and Structure of Macromolecules, Cold Spring Harbor Symposia on Quantitative Biology, vol. 28 (1963), p. 559. 4 Doctor, B. P., J. Apgar, and R. W. Holley, J. Biol. Chem., 236, 1117 (1961). 6 Weisblum, B., S. Benzer, and R. W. Holley, these PROCEEDINGS, 48, 1449 (1962). 6 von Ehrenstein, G., and D. Dais, these PROCEEDINGS, 50, 81 (1963). 7 Sueoka, N., and T. Yamane, these PROCEEDINGS, 48, 1454 (1962). 8 Yamane, T., T. Y. Cheng, and N. Sueoka, in Synthesis and Structure of Macromolecules, Cold Spring Harbor Symposia on Quantitative Biology, vol. 28 (1963), p. 569. 9 Benzer, S., personal communication. 10 Bennett, T. P., in Synthesis and Structure of Macromolecules, Cold Spring Harbor Symposia on Quantitative Biology, vol. 28 (1963), p. 577. 11 Yamane, T., and N. Sueoka, these PROCEEDINGS, 50, 1093 (1963). 12 Berg, P., F. H. Bergmann, E. J. Ofengand, and M. Dieckmann, J. Biol. Chem., 236, 1726 (1961). 13Bennett, T. P., J. Goldstein, and F. Lipmann, these PROCEEDINGS, 49, 850 (1963). 14 Keller, E. B., and R. S. Anthony, Federation Proc., 22, 231 (1963). ASPECTS OF CONTROL OF PROTEIN SYNTHESIS IN NORMAL AND REGENERATING RA T LIVER, I. A MICROSOMAL INHIBITOR OF AMINO ACID INCORPORATION WHOSE ACTION IS ANTAGONIZED BY GUANOSINE TRIPHOSPHATE* BY MAHLON B. HOAGLAND, OSCAR A. SCORNIK, AND LORRAINE C. PFEFFERKORN DEPARTMENT OF BACTERIOLOGY AND IMMUNOLOGY, HARVARD MEDICAL SCHOOL, BOSTON Communicated by John T.
  • Download Product Insert (PDF)

    Download Product Insert (PDF)

    PRODUCT INFORMATION Guanosine Item No. 27702 CAS Registry No.: 118-00-3 Synonyms: Guanine Ribonucleoside, NSC 19994 N O MF: C10H13N5O5 FW: 283.2 N O OH Purity: ≥98% N N UV/Vis.: λmax: 254 nm Supplied as: A crystalline solid H OH OH H N Storage: -20°C 2 Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Guanosine is supplied as a crystalline solid. A stock solution may be made by dissolving the guanosine in the solvent of choice, which should be purged with an inert gas. Guanosine is soluble in the organic solvent DMSO at a concentration of approximately 30 mg/ml. Guanosine is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, guanosine should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Guanosine has a solubility of approximately 0.16 mg/ml in a 1:5 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Guanosine is a purine nucleoside that is comprised of the purine base guanine attached to a ribose moiety.1 Mono-, di-, tri-, and cyclic monophosphorylated forms of guanosine (GMP, GDP, GTP, and cGMP, respectively) are essential for a variety of endogenous biochemical processes, such as signal transduction, metabolism, and RNA synthesis.2-4 References 1. Voet, D. and Voet, J.G. 3rd ed., John Wiley & Sons, Hoboken, NJ (2004). 2. Hanson, R.W. and Garber, A.J.